M&A in the Contract Manufacturing Industry: Implications and Outlook – 2018 Edition
List Price: US $4,995
This repoprt analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015–2017 and assesses the implications for acquirers and sellers of such services. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.
There were 130 acquisitions of service providers during the three-year period from 2015–2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs—small molecule, dose, and analytical services.
Who should buy this report?
This 52-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for:
- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking